Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04936529 · ClinicalTrials.gov registry record · Phase 2
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
A Phase 2 study of Neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 286
- Enrollment target
- 1
- Study location
NCT04936529 is a Phase 2 study of Neuroblastoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 286 participants, above the 236-participant average among 94 other Neuroblastoma trials with a reported enrollment target (21% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04936529, a Phase 2 study of Neuroblastoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 286 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to explore the combination of a bivalent vaccine, a sugar called beta-glucan (β-glucan), and a protein called granulocyte-macrophage colony stimulating factor (GM-CSF) as an effective treatment for people with high-risk neuroblastoma that is in complete remission. The combination may be effective because the different parts of the treatment work to strengthen the immune system's response against cancer cells in different ways.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT β-glucan
- DRUG GM-CSF
- BIOLOGICAL OPT-821
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 286 participants |
| Start Date | 2021-08-02 |
| Est. Completion | 2026-06-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04936529
The ClinicalTrials.gov registry entry for NCT04936529 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 286 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 236-participant average among 94 other Neuroblastoma trials with a reported enrollment target (21% higher). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuroblastoma appearing as the primary indexed condition, and to 3 interventions - of which β-glucan is the first listed.
NCT04936529 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04936529 about?
NCT04936529 is a clinical study titled "A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma". The purpose of the study is to explore the combination of a bivalent vaccine, a sugar called beta-glucan (β-glucan), and a protein called granulocyte-macrophage colony stimulating factor (GM-CSF) as an effective treatment for people with high-risk neuroblastoma that is in complete remission. The com...
What is the current status of trial NCT04936529?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 286 participants. The study started on 2021-08-02. Estimated completion is 2026-06-15.
What conditions does trial NCT04936529 study?
This clinical trial studies the following conditions: Neuroblastoma.
What interventions are being tested in trial NCT04936529?
The interventions under investigation include: β-glucan (DIETARY_SUPPLEMENT), GM-CSF (DRUG), OPT-821 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04936529?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04936529 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
RECRUITING · Phase 2
-
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
RECRUITING · Phase 2
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
-
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
RECRUITING · Phase 2
-
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
RECRUITING · Phase 2
-
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.